{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:15:28Z","timestamp":1791220528956,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T00:00:00Z","timestamp":1410480000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00280-014-2576-8","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T08:43:16Z","timestamp":1410424996000},"page":"1039-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A first-in-human study of the anti-\u03b15\u03b21 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors"],"prefix":"10.1007","volume":"74","author":[{"given":"J.","family":"Mateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Keedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mugundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abbattista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gallo Stampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,12]]},"reference":[{"key":"2576_CR1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines in their roles as major adhesion receptors, integrins. Cell 110:673\u2013687","journal-title":"Cell"},{"key":"2576_CR2","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1038\/ncb0402-e83","volume":"4","author":"CK Miranti","year":"2002","unstructured":"Miranti CK, Brugge JS (2002) Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 4:E83\u2013E90","journal-title":"Nat Cell Biol"},{"key":"2576_CR3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1083\/jcb.132.1.227","volume":"132","author":"K Wennerberg","year":"1996","unstructured":"Wennerberg K, Lohikangas L, Gullberg D, Pfaff M, Johansson S, F\u00e4ssler R (1996) Beta 1 integrin-dependent and -independent polymerization of fibronectin. J Cell Biol 132:227\u2013238","journal-title":"J Cell Biol"},{"key":"2576_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1083\/jcb.122.1.209","volume":"122","author":"JS Bauer","year":"1993","unstructured":"Bauer JS, Varner J, Schreiner C, Kornberg L, Nicholas R, Juliano RL (1993) Functional role of the cytoplasmic domain of the integrin alpha 5 subunit. J Cell Biol 122:209\u2013221","journal-title":"J Cell Biol"},{"key":"2576_CR5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bjc.6601576","volume":"90","author":"H Jin","year":"2004","unstructured":"Jin H, Varner J (2004) Integrins: roles in cancer development and as treatment targets. Br J Cancer [Internet] 90:561\u2013565","journal-title":"Br J Cancer [Internet]"},{"key":"2576_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1242\/dev.113.1.327","volume":"113","author":"JL Muschler","year":"1991","unstructured":"Muschler JL, Horwitz AF (1991) Down-regulation of the chicken alpha 5 beta 1 integrin fibronectin receptor during development. Development 113:327\u2013337","journal-title":"Development"},{"key":"2576_CR7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1242\/dev.119.4.1093","volume":"119","author":"JT Yang","year":"1993","unstructured":"Yang JT, Rayburn H, Hynes RO (1993) Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119:1093\u20131105","journal-title":"Development"},{"issue":"22","key":"2576_CR8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.ATV.0000016045.93313.F2","volume":"1","author":"SE Francis","year":"2002","unstructured":"Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D et al (2002) Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 1(22):927\u2013933","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2576_CR9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9440(10)65005-5","volume":"156","author":"S Kim","year":"2000","unstructured":"Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345\u20131362","journal-title":"Am J Pathol"},{"issue":"3","key":"2576_CR10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/mp400535v","volume":"11","author":"MM Adil","year":"2014","unstructured":"Adil MM, Levine RM, Kokkoli E (2014) Increasing cancer-specific gene expression by targeting overexpressed \u03b15\u03b21 integrin and upregulated transcriptional activity of NF-\u03baB. Mol Pharm 11(3):849\u2013858","journal-title":"Mol Pharm"},{"issue":"14","key":"2576_CR11","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","volume":"1","author":"AD Ricart","year":"2008","unstructured":"Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 1(14):7924\u20137929","journal-title":"Clin Cancer Res"},{"issue":"121","key":"2576_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","volume":"1","author":"KM Bell-McGuinn","year":"2011","unstructured":"Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT et al (2011) A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 1(121):273\u2013279","journal-title":"Gynecol Oncol"},{"key":"2576_CR13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"B Besse","year":"2013","unstructured":"Besse B, Tsao LC, Chao DT, Fang Y, Soria J-C, Almokadem S et al (2013) Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 24:90\u201396","journal-title":"Ann Oncol"},{"key":"2576_CR14","doi-asserted-by":"crossref","unstructured":"Zhang L, Stock J, Elliot M, Chen E, Nguyen T, Wong A et al (2013) Abstract 2336: assessment of mechanisms of action (MOAs) of the Fc-engineered integrin \u03b15\u03b21 targeting antibody PF-04605412 in human integrin \u03b15 knock-in mice. Cancer Res. p. abstract 2336","DOI":"10.1158\/1538-7445.AM2013-2336"},{"issue":"23","key":"2576_CR15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","volume":"20","author":"SP Treon","year":"2005","unstructured":"Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E et al (2005) Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. J Clin Oncol 20(23):474\u2013481","journal-title":"J Clin Oncol"},{"issue":"95","key":"2576_CR16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1073\/pnas.95.2.652","volume":"20","author":"R Clynes","year":"1998","unstructured":"Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 20(95):652\u2013656","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2576_CR17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443\u2013446","journal-title":"Nat Med"},{"key":"2576_CR18","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"issue":"25","key":"2576_CR19","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"10","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 10(25):5616\u20135623","journal-title":"J Clin Oncol"},{"issue":"28","key":"2576_CR20","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","volume":"1","author":"RL Ferris","year":"2010","unstructured":"Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 1(28):4390\u20134399","journal-title":"J Clin Oncol"},{"issue":"28","key":"2576_CR21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"1","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 1(28):1124\u20131130","journal-title":"J Clin Oncol"},{"issue":"20","key":"2576_CR22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","volume":"1","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 1(20):719\u2013726","journal-title":"J Clin Oncol"},{"key":"2576_CR23","doi-asserted-by":"crossref","unstructured":"Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ et al (2014) Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving Trastuzumab. Oncol 19(3):228\u2013234","DOI":"10.1634\/theoncologist.2013-0286"},{"issue":"14","key":"2576_CR24","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","volume":"1","author":"AD Ricart","year":"2008","unstructured":"Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 1(14):7924\u20137929","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2576_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000055403","volume":"61","author":"N Cook-Burns","year":"2001","unstructured":"Cook-Burns N (2001) Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2):58\u201366","journal-title":"Oncology"},{"key":"2576_CR26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.112.191999","volume":"341","author":"KT Luu","year":"2012","unstructured":"Luu KT, Bergqvist S, Chen E, Hu-lowe D, Kraynov E (2012) A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341:702\u2013708","journal-title":"J Pharmacol Exp Ther"},{"key":"2576_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10928-013-9344-y","volume":"41","author":"L Gibiansky","year":"2014","unstructured":"Gibiansky L, Gibiansky E (2014) Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn 41:35\u201347","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2576-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2576-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2576-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T21:28:43Z","timestamp":1650144523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2576-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,12]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2576-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,12]]}}}